Immunogenicity of a reduced-dose whole killed rabies vaccine is significantly enhanced by ISCOMATRIX™ adjuvant, Merck amorphous aluminum hydroxylphosphate sulfate (MAA) or a synthetic TLR9 agonist in rhesus macaques

Vaccine

Volumn 31, Issue 42, 2013, Pages 4888-4893

  DiStefano, Daniel ^a   Antonello, Joseph M ^a   Bett, Andrew J ^a   Medi, Muneeswara B ^a   Casimiro, Danilo R ^a   ter Meulen, Jan ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADJUVANT; AMORPHOUS ALUMINUM HYDROXYLPHOSPHATE SULFATE; IMMUNE MODULATORY OLIGONUCLEOTIDE; IMMUNOMODULATING AGENT; IMO 2170; ISCOMATRIX; NEUTRALIZING ANTIBODY; RABIES IMMUNOGLOBULIN; RABIES VACCINE; SAPONIN; TOLL LIKE RECEPTOR 9; TOLL LIKE RECEPTOR AGONIST; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANTIBODY RESPONSE; ANTIBODY TITER; ARTICLE; DRUG DOSAGE FORM COMPARISON; DRUG DOSE REDUCTION; DRUG FORMULATION; FEMALE; FLUORESCENCE; IMMUNOGENICITY; MALE; NONHUMAN; PRIORITY JOURNAL; RABIES; RAPID FLUORESCENT FOCUS INHIBITION TEST; RHESUS MONKEY; SEROLOGY; TREATMENT RESPONSE; VACCINATION;

ADJUVANTS, IMMUNOLOGIC; ALUMINUM COMPOUNDS; ANIMALS; ANTIBODIES, NEUTRALIZING; ANTIBODIES, VIRAL; CHOLESTEROL; DRUG COMBINATIONS; FEMALE; INJECTIONS, INTRAMUSCULAR; MACACA MULATTA; MALE; NEUTRALIZATION TESTS; PHOSPHATES; PHOSPHOLIPIDS; RABIES; RABIES VACCINES; SAPONINS; SULFATES; TOLL-LIKE RECEPTOR 9; VACCINES, INACTIVATED;

EID: 84884169743     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2013.07.034     Document Type: Article

References (35)

1. Atkinson A.J., Huang S.-M., Lertora J.J.L., Markey S.P. Principles of clinical pharmacology 2012, Elsevier, London. 3rd ed.
2. Berlin B.S. Rabies vaccine adsorbed: neutralizing antibody titers after three-dose pre-exposure vaccination. American Journal of Public Health 1990, 80(4):476-478.
3. Bunschoten H., Klapmuts R.J., Claassen I.J., Reyneveld S.D., Osterhaus A.D., Uytdehaag F.G. Rabies virus-specific human T cell clones provide help for an in vitro antibody response against neutralizing antibody-inducing determinants of the viral glycoprotein. Journal of General Virology 1989, 70(Pt. 6):1513-1521.
4. Caulfield M.J., Shi L., Wang S., Wang B., Tobery T.W., Mach H., Ahl P.L., Cannon J.L., Cook J.C., Heinrichs J.H., Sitrin R.D. Effect of alternative aluminum adjuvants on the absorption and immunogenicity of HPV16 L1 VLPs in mice. Human Vaccine 2007, 3(4):139-145.
5. Cox J.H., Lothar G.S. Prophylactic immunization of humans against rabies by intradermal inoculation of human diploid cell culture vaccine. Journal of Clinical Microbiology 1976, 3(2):96-101.
6. Drane D., Gittleson C., Boyle J., Maraskovsky E. ISCOMATRIX™ adjuvant for prophylactic and therapeutic vaccines. Expert Review of Vaccines 2007, 6(5):761-772.
7. Duewell P., Kisser U., Heckelsmiller K., Hoves S., Stoitzner P., Koernig S., et al. ISCOMATRIX adjuvant combines immune activation with antigen delivery to dendritic cells in vivo leading to effective cross-priming of CD8+ T cells. Journal of Immunology 2011, 187(1):55-63.
8. Eisenbarth S.C., Colegio O.R., O'Connor W., Sutterwala F.S., Flavell R.A. Crucial role for the Nalp3 inflammasome in the immunostimulatory properties of aluminium adjuvants. Nature 2008, 453(7198):1122-1126.
9. Fenje P., Pinteric L. Potentiation of tissue culture rabies vaccine by adjuvants. American Journal of Public Health and the Nation's Health 1966, 56(12):2106-2113.
10. Ghimire T.R., Benson R.A., Garside P., Brewer J.M. Alum increases antigen uptake, reduces antigen degradation and sustains antigen presentation by DCs in vitro. Immunology Letters 2012, 147(1/2):55-62.
11. Hooper D.C., Morimoto K., Bette M., Weihe E., Koprowski H., Dietzschold B. Collaboration of antibody and inflammation in clearance of rabies virus from the central nervous system. Journal of Virology 1998, 72(5):3711-3719.
12. Johnson N., Cunningham A.F., Fooks A.R. The immune response to rabies virus infection and vaccination. Vaccine 2010, 28(23):3896-3901.
13. Klinman D.M., Klaschik S., Tomaru K., Shirota H., Tross D., Ikeuchi H. Immunostimulatory CpG oligonucleotides: effect on gene expression and utility as vaccine adjuvants. Vaccine 2010, 28(8):1919-1923.
14. Lin F.T., Lina N. Developments in the production and application of rabies vaccine for human use in China. Tropical Doctor 2000, 30(1):14-16.
15. Liu Q., Ertl H.C. Preventative childhood vaccination to rabies. Expert Opinion on Biological Therapy 2012, 12(8):1067-1075.
16. Mifune K., Takeuchi E., Napiorkowski P.A., Yamada A., Sakamoto K. Essential role of T cells in the postexposure prophylaxis of rabies in mice. Microbiology and Immunology 1981, 25(9):895-904.
17. Moore S.M., Wilkerson M.J., Davis R.D., Wyatt C.R., Briggs D.J. Detection of cellular immunity to rabies antigens in human vaccinees. Journal of Clinical Immunology 2006, 26(6):533-545.
18. Morein B., Hu K.-F., Abusugra I. Current status and potential applications of ISCOMS in veterinary medicine. Advanced Drug Delivery Reviews 2004, 56:1367-1382.
19. Morelli A.B., Becher D., Koernig S., Silva A., Drane D., Maraskovsky E.ISCOMATRIX: a novel adjuvant for use in prophylactic and therapeutic vaccines against infectious diseases. Journal of Medical Microbiology 2012, 61:935-943.
20. Perry L.L., Lodmell D.L. Role of CD4+ and CD8+ T cells in murine resistance to street rabies virus. Journal of Virology 1991, 65:3429-3434.
21. Putta M.R., Yu D., Bhagat L., Wang D., Zhu F.G., Kandimalla E.R. Impact of nature and length of linker incorporated in agonists on toll-like receptor 9-mediated immune responses. Journal of Medicinal Chemistry 2010, 53(9):3730-3738.
22. Roukens A., Vossen A., Vandissel J., Visser L. Reduced dose pre-exposure primary and booster intradermal rabies vaccination with a purified chick embryo cell vaccine (PCECV) is immunogenic and safe in adults. Vaccine 2008, 26:3438-3442.
23. Sabchareon A., Chantavanich P., Pasuralertsakul S., Pojjaroen-Anant C., Prarinyanupharb V., Attanath P., et al. Persistence of antibodies in children after intradermal or intramuscular administration of preexposure primary and booster immunizations with purified vero cell rabies vaccine. Pediatric Infectious Disease Journal 1998, 17:1001-1007.
24. Shantavasinkul P., Tantawichien T., Wilde H., Sawangvaree A., Kumchat A., Ruksaket N., et al. Postexposure rabies prophylaxis completed in 1 week: preliminary study. Clinical Infectious Diseases 2010, 50:56-60.
25. Smith J.S., Yager P.A., Baer G.M. A rapid reproducible test for determining rabies neutralizing antibody. Bulletin of the World Health Organization 1973, 48:535-541.
26. Struthers M., Bett A.J., Wisniewski T., Dubey S.A., Precopio M., Jiang W., et al. Synthesis and immunological activities of novel agonists of Toll-like receptor 9. Cellular Immunology 2010, 263(1):105-113.
27. Sudarshan M.K., Bhardwaj S., Mahendra B.J., Sharma H., Sanjay T.V., Ashwathnarayana D.H., Bilagumba G. An immunogenicity, safety and post-marketing surveillance of a novel adsorbed human diploid cell rabies vaccine (Rabivax) in Indian subjects. Human Vaccine 2008, 4(4):275-279.
28. Turner G.S. Thymus dependence of rabies vaccine. Journal of General Virology 1976, 33:535-538.
29. Wang X., Bao M., Wan M., Wei H., Wang L., Yu Y., et al. A CpG oligonucleotide acts as a potent adjuvant for inactivated rabies virus vaccine. Vaccine 2008, 26:1893-1901.
30. Warrell M.J., Warrell D.A., Suntharasamai P., Viravan C., Sinhaseni A., Udomsakdi D., et al. An economical regimen of human diploid cell strain anti-rabies vaccine for post-exposure prophylaxis. Lancet 1983, 2(8345):301-304.
31. Warrell M.J. Current rabies vaccines and prophylaxis schedules: preventing rabies before and after exposure. Travel Medicine and Infectious Disease 2012, 10:1-15.
32. Warrell M.J. Intradermal rabies vaccination: the evolution and future of pre- and post-exposure prophylaxis. Current Topics in Microbiology and Immunology 2012, 351:139-157.
33. WHO Position Paper on Rabies. Weekly Epidemiological Record 2010, 85:309-320.
34. Wilde H. Rabies post-exposure vaccination. Are Antibody Responses Adequate?. Clinical Infectious Diseases 2012, 55:206-208.
35. Working Group II, WHO Expert Committee Vaccine potency requirements for reduced immunization schedules and pre-exposure treatment. Developments in Biological Standardization 1978, 40:268-270.